| An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia S Ragaini, S Wagner, G Marconi, S Parisi, C Sartor, J Nanni, G Cristiano, ... Blood Advances 6 (1), 87-99, 2022 | 15 | 2022 |
| Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry MK Tilch, C Visco, S Kinda, O Hermine, M Kohn, C Besson, S Lamure, ... HemaSphere 6 (5), e0711, 2022 | 8 | 2022 |
| Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma E Genuardi, P Klous, B Mantoan, D Drandi, M Ferrante, F Cavallo, ... Hematological Oncology 39 (3), 293-303, 2021 | 6 | 2021 |
| Real life use of bendamustine in elderly patients with lymphoid neoplasia I Dogliotti, S Ragaini, F Vassallo, E Boccellato, G De Luca, F Perutelli, ... Journal of Personalized Medicine 11 (4), 249, 2021 | 6 | 2021 |
| MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia G Marconi, A Talami, MC Abbenante, C Sartor, S Parisi, J Nanni, ... European Journal of Haematology 105 (1), 47-55, 2020 | 6 | 2020 |
| Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up M Parisi, I Dogliotti, M Clerico, D Bertuzzo, G Benevolo, L Orsucci, ... European Journal of Neurology 29 (12), 3611-3622, 2022 | 5 | 2022 |
| Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients G Marconi, S De Polo, G Martinelli, J Nanni, L Bertamini, A Talami, M Olivi, ... Leukemia Research 101, 106497, 2021 | 4 | 2021 |
| P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL. B Alessandria, E Genuardi, AM Civita, D Drandi, B Mantoan, M Ferrante, ... HemaSphere 6, 1130-1131, 2022 | 3 | 2022 |
| COVID-19 in a post-transplant heart recipient who developed aggressive lymphoma: a biphasic course during rituximab treatment M Clerico, I Dogliotti, A Calcagno, D Grimaldi, S Leone, S Ragaini, ... Hemasphere 5 (7), e592, 2021 | 3 | 2021 |
| Quantitative assessment of indoleamine 2, 3-dioxygenase (IDO) expression at diagnosis predicts clinical outcome in patients with acute myeloid leukemia undergoing allogeneic … S Parisi, S Ragaini, D Ocadlikova, M Lecciso, G Marconi, S Paolini, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 3 | 2018 |
| Kinematics of the Galactic Populations Towards the NGP A Vallenari, S Pasetto, G Bertelli, C Chiosi, S Ragaini, A Spagna Milky Way Surveys: The Structure and Evolution of our Galaxy 317, 203, 2004 | 3 | 2004 |
| HBV reactivation in patients with past infection affected by non-Hodgkin lymphoma and treated with anti-CD20 antibody based immuno-chemotherapy: A multicenter experience M Clerico, I Dogliotti, P Ghione, VR Zilioli, F Merli, B Botto, W Al Essa, ... Journal of Personalized Medicine 12 (2), 285, 2022 | 2 | 2022 |
| Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports S Ferrero, S Ragaini Journal of Medical Case Reports 15, 1-4, 2021 | 2 | 2021 |
| A three-gene immune signature including IDO1, BIN1 and PLXNC1 predicts survival in acute Myeloid Leukemia S Ragaini, S Wagner, G Marconi, S Parisi, C Sartor, J Nanni, G Cristiano, ... Blood 136, 35-36, 2020 | 2 | 2020 |
| Mitoxantrone, etoposide and cytarabine (MEC) can induce deep complete remission and is an effective bridge therapy to allotransplantation (SCT) in refractory/relapsed acute … G Marconi, A Talami, MC Abbenante, S Paolini, C Sartor, S Parisi, ... Blood 132, 4036, 2018 | 2 | 2018 |
| Non-Hodgkin lymphoma treated with anti-CD20 antibody-based immunochemotherapy M Clerico, S Ragaini, F Cavallo Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal, 103-122, 2024 | | 2024 |
| Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma L Nassi, G Martino, B Botto, M Paulli, R Bruna, M Palazzo, A Parisi, ... Blood 142, 4503, 2023 | | 2023 |
| MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2:: IGH Marker: A Substudy from the Fondazione … E Genuardi, B Alessandria, I Della Starza, F Guerrini, R Bomben, ... Blood 142, 4373, 2023 | | 2023 |
| Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (> 24 months): the LATE‐POD study C Visco, C Malinverni, E Florea, I Glimelius, M Mirandola, ... Hematological Oncology 41, 474-475, 2023 | | 2023 |
| Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi … F Cordero, S Ferrero, S Pernice, E Genuardi, R Sirovich, B Alessandria, ... Blood 140 (Supplement 1), 9375-9377, 2022 | | 2022 |
